Gilead Reports Higher HIV Prevention Persistence With Twice-Yearly Lenacapavir
Gilead said PURPOSE 5 trial results showed significantly higher persistence with twice-yearly injectable lenacapavir than with daily oral F/TDF for HIV prevention.
Story updates
05:16:22 PM UTC
SquawkNews
In the Phase 2 PURPOSE 5 trial, 52-week persistence was higher with twice-yearly lenacapavir than daily F/TDF. No HIV acquisitions occurred in the lenacapavir group; one occurred in the F/TDF group, where drug levels indicated fewer than two doses per week.Material DetailsContext by AI AnalystThis…